（其实生物里有些应用方面的研究还是挺好玩的。就是付出和收获不成正比。我六年前
不去Novartis,就是因为对筛药有兴趣。作出一个药的可能性比中lottery的机会还小。
这个行当真的只合适不愁吃穿的人。回头看看，真希望当年转了行。可太太英文不通找
不到工作，一个家要养，还有两边父母要照顾，这些年我有多少无奈！好在太太愿意和
我一起吃苦，一起为小家奋斗，一步一步，我们也终于看得见隧道那头的亮光了。两边
父母的任务接近完成，孩子一个大学毕业一个也快上大学了。我和太太说，最差就是卖
了房子给儿子上大学，我们自己租个小房子住。
不管你转不转行，早点学习投资理财还是要的。没有希望的日子最难熬，如何把枯燥的
日子过得有希望，也是生活的艺术。我等太太从国内外回来就准备庆祝我们结婚25周年
了。没有钻戒，没有鸽子蛋。但60岁之前退休是我给太太的承诺。下面是我和太太开玩
笑的一个梦，但当太太从local报纸上看到我们研究的报道，她说：真的哟，都上报纸
了。这个要成功了，咱们可以搬到一个气候好的地方舒服舒服地退休了。）
投资理财坛最近流行千万梦，俺博士后挣得少，还不能冒险，能不能也有一个千万梦呢？
昨天老板把试验室的人召集起来，先让学校的摄影师拍好照，作press release的准备
；再给我们开了个小会，说找好了律师，要正式办一个皮包公司了。虽然专利能不能拿
到还不知道，但公司的运作还是要的。老板从没办过公司，都是律师指示作什么，他就
照办：先分配专利的所有权。俺居然拿到了4.5%的share。。。
他鼓励大家：不要说我们作的东西没有钱途。最近的例子就是针对抗药性前列腺癌的药
物，也是一个大学教授搞出来的，后来自己办公司，临床试验等等等，最后卖了1.2B。
而那个教授这次是杂志特约审我们文章的。。。
希望借他的仙气，卖个250M,我不就千万级了么。
哈哈，博士后也可以有梦么。从今天开始，米不用数了，数千万。：）））。
（二0一五年三月二十日）
这就是生物人的梦（ZT)：
ARN-509, A Next Generation Anti-Androgen: From Discovery to Clinical
Development
Richard Heyman, PhD，Aragon Pharmaceuticals
October 26, 2012—Castration-resistant prostate cancer (CRPC) is defined by
tumor growth, even with lowered blood levels of testosterone, which is a
male androgen hormone. This form of prostate cancer is marked by resistance
to drugs—such as leuprolide, gosereline or casodex—that either lower the
amount of testosterone in the blood or the persistence of the androgen
receptor (AR) signaling. (Androgens can fuel prostate cancer progression; AR
binds to testosterone in the cytoplasm and ushers it into the cell’s
nucleus, allowing it to give “instructions” that trigger changes in
transcriptional signaling that drive tumor proliferation. Currently there
are several anti-androgen drugs on the market to treat advanced prostate
cancer. By definition, anti-androgen drugs bind to the AR protein and block
its function.
A novel second-generation anti-androgen drug, ARN-509, was discovered by PCF
-funded researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) in New
York and UCLA and the compound has recently entered Phase II clinical
trials being conducted MSKCC and 13 others across the U.S.
Aragon Pharmaceuticals, based in San Diego, has licensed the ARN-509 and is
conducting the studies in men with CRPC to determine safety, tolerability
and anti-tumor activity of the drug. Preclinical data show that this second-
generation anti-androgen, ARN-509 is more efficacious in models of CRPC,
thus making it a potentially more effective anti-androgen drug than first-
generation compounds. Early results from the Phase I portion of the study
showed that about half of patients receiving ARN-509 experienced PSA
declines of 50 percent or greater during the trial period.
During a discussion at the 19th Annual PCF Scientific Retreat Dr. Richard
Heyman of Aragon discussed the preclinical work in rodents—e.g., robust
tumor regression in CRPC mouse models and low brain tissue exposure and
better results compared to a standard drug used to treat CRPC—that led to
the human clinical trials now underway.
He spoke of the excellent safety profile seen to date in Phase I clinical
trials and the establishment of the recommended Phase II dose. In addition,
PET imaging of men with CRPC receiving ARN-509 demonstrates robust AR
blockade after four weeks of treatment.
To date, approximately 100 men are enrolled in the Phase II study with
robust PSA responses in three individual cohorts of the CRPC patients. The
drug at the established recommended dose continues to be well-tolerated.
During the Q & A session that followed the presentation, Dr. Heyman was
asked if they would be doing trials of ARN-509 in comparison to Xtandi (also
a 2nd generation anti-androgen) in the future; he responded that his
company is exploring all the options.
PCF Funding: Charles Sawyers, One of the key scientists behind the discovery
of ARN-509 has received major PCF funding over the span of many years.
